Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29624640 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3MAPTELANE | |
| SCHEMBL4035983 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3MAPTELANE | |
| SCHEMBL4035987 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3MAPTELANE | |
| SCHEMBL29261319 | 0.88 | CHRM2 (0.39) | CHRM2CHRM1CHRM3MAPTELANE | |
| SCHEMBL29261316 | 0.88 | CHRM2 (0.39) | CHRM2CHRM1CHRM3MAPTELANE | |
| SCHEMBL29261317 | 0.88 | CHRM2 (0.39) | CHRM2CHRM1CHRM3MAPTELANE | |
| SCHEMBL3378115 | 0.85 | CHRM2 (0.40) | CHRM2CHRM1CHRM3MAPTNPC1 | |
| SCHEMBL14141084 | 0.85 | CHRM2 (0.40) | CHRM2CHRM1CHRM3MAPTNPC1 | |
| SCHEMBL27378721 | 0.84 | CHRM2 (0.38) | CHRM2CHRM1CHRM3MAPTELANE | |
| SCHEMBL31080746 | 0.80 | CHRM2 (0.36) | CHRM2CHRM1CHRM3MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055156-A | (R) -N-ethyl-5-fluoro-N-isopropyl-2- ((5- (2- (6- ((2-methoxyethyl) (methyl) amino) -2-methyl-hex-3-yl) -2, 6-diazaspiro [3.4] oct-6-yl) -1,2, 4-triazin-6-yl) oxy) benzamide, formulations and dosing regimens for treating cancer | 詹森药业有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260125387-A1 | (R)-N-ETHYL-5-FLUORO-N-ISOPROPYL-2-((5-(2-(6-((2-METHOXYETHYL)(METHYL)AMINO)-2-METHYLHEXAN-3-YL)-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-1,2,4-TRIAZIN-6-YL)OXY)BENZAMIDE BESYLATE SALT | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-07 | — | — | US | disclosed |
| EP-4698182-A1 | COMBINATION OF A MENIN-LL1 INHIBITOR, A DNA INTERCALATING AGENT AND A PYRIMIDINE ANALOGUE TO TREAT A HEMATOPOIETIC DISORDER | Janssen Pharmaceutica NV (BE) | 2026-02-25 | — | — | EP | disclosed |
| US-12473295-B2 | Substituted straight chain spiro derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-18 | — | — | US | disclosed |
| US-20250302840-A1 | COMBINATION THERAPIES | JANSSEN-CILAG (FR) | 2025-10-02 | — | — | US | disclosed |
| WO-2025082444-A2 | (R) -N-ETHYL-5-FLUORO-N-ISOPROPYL-2- ( (5- (2- (6- ( (2-METHOXYETHYL) (METHYL) AMINO) -2-METHYLHEXAN-3-YL) -2, 6-DIAZASPIRO [3.4] OCTAN-6-YL) -1, 2, 4-TRIAZIN-6-YL) OXY) BENZAMIDE, FORMULATIONS AND DOSAGE REGIMENS THEREOF, FOR USE IN TREATING CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-24 | — | — | WO | disclosed |
| CN-118845786-A | Combination therapy | 詹森药业有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118845787-A | Combination therapy | 詹森药业有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118852178-A | Compounds for the treatment of diseases such as cancer | 詹森药业有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2024218072-A1 | COMBINATION OF A MENIN-LL1 INHIBITOR, A DNA INTERCALATING AGENT AND A PYRIMIDINE ANALOGUE TO TREAT A HEMATOPOIETIC DISORDER. | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-24 | — | — | WO | disclosed |
| WO-2022237719-A1 | COMBINATION THERAPIES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022237719-A1 | COMBINATION THERAPIES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| EP-4077312-A1 | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES | Janssen Pharmaceutica NV (BE) | 2022-10-26 | — | — | EP | disclosed |
| CN-114867721-A | Substituted straight-chain spiro derivatives | 詹森药业有限公司 | 2022-08-05 | — | — | CN | disclosed |
| WO-2021121327-A1 | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | WO | disclosed |
| US-10717754-B2 | Metal complexes | UNIVERSITY OF LEEDS (GB) | 2020-07-21 | — | — | US | disclosed |
| EP-3390421-B1 | METAL COMPLEXES | UNIV LEEDS INNOVATIONS LTD (GB) | 2020-01-29 | — | — | EP | disclosed |
| US-20180362566-A1 | METAL COMPLEXES | UNIVERSITY OF LEEDS (GB) | 2018-12-20 | — | — | US | disclosed |
| EP-3390421-A1 | METAL COMPLEXES | University of Leeds (GB) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017103623-A1 | METAL COMPLEXES | UNIVERSITY OF LEEDS (GB) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302840-A1 | COMBINATION THERAPIES | MEN1, MLLT1, BMI1 | CHRM2 1335/4885CHRM1 1622/4885CHRM3 3205/4885 |
| US-12473295-B2 | Substituted straight chain spiro derivatives | MLLT1, MEN1, MLLT3 | CHRM2 4836/4885CHRM1 4829/4885CHRM3 4796/4885 |
| US-10717754-B2 | Metal complexes | SDHB, MPI, AP1M1 | CHRM2 4775/4885CHRM1 4703/4885CHRM3 4702/4885 |
| US-20180362566-A1 | METAL COMPLEXES | SDHB, AP1M1, GFPT1 | CHRM2 4790/4885CHRM1 4696/4885CHRM3 4693/4885 |
| US-20260125387-A1 | (R)-N-ETHYL-5-FLUORO-N-ISOPROPYL-2-((5-(2-(6-((2-METHOXYETHYL)(METHYL)AMINO)-2-METHYLHEXAN-3-YL)-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-1,2,4-TRIAZIN-6-YL)OXY)BENZAMIDE BESYLATE SALT | MLLT1, MEN1, MLLT3 | CHRM2 4166/4885CHRM1 4293/4885CHRM3 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.